Ameya Laboratories Peer Comparison

BSE: 532981

₹0.24

₹0.00 (0.00%)

As on 16-Mar-2015IST

Market cap

₹6 Cr

Revenue (TTM)

₹160 Cr

P/E Ratio

--

P/B Ratio

--

Div. Yield

0 %

Edit

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	6	37,212	27,783	26,915	27,712
Revenue (₹ Cr)	160	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-19.78	414.00	288.22	387.35	-371.81
Net Margin (%)	-12.32	11.23	14.79	26.01	-3.93
RoE (%)	-12.38	8.38	29.77	25.18	-3.85
Price to Earnings	--	90.98	96.40	69.69	--
Price-To-Book	--	7.39	20.70	15.60	3.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	268.04	4,350.50	34.80	33.90	--
Total Income	268.62	4,375.84	34.80	34.61	--
Total Expenditure	228.49	2,996.79	25.65	30.42	--
EBITDA	39.55	1,353.71	9.15	3.48	--
Depreciation	7.68	115.07	2.71	1.05	--
EBIT	31.88	1,238.64	6.44	2.42	--
Interest	25.54	269.02	2.51	1.10	--
Other Income	0.58	25.34	0.42	0.71	--
Exceptional Items	-0.56	-473.77	--	--	--
Profit before Tax	6.35	521.19	3.93	2.03	--
Provision for Tax	2.91	221.74	1.40	0.68	--
Profit after Tax	3.44	299.45	2.52	1.35	--

Liabilities (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	165.42	1,471.02	37.49	6.11	--
Minority Interest	--	--	--	--	--
Non-Current Liabilities	54.07	2,891.88	5.39	0.04	--
Current Liabilities	114.49	1,890.94	24.92	15.82	--
Total Liabilities	333.98	6,253.84	67.79	22.09	--

Assets (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	162.68	3,772.33	47.64	5.51	--
Current Assets	169.64	2,481.51	20.15	16.45	--
Total Assets	333.98	6,253.84	67.79	22.09	--
Total Debt*	130.84	3,492.50	19.14	6.41	--
Net Current Assets	55.15	590.57	-4.76	0.63	--
Contingent Liabilities	2.21	46.91	0.71	--	--

Cashflow (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-10.13	1,343.83	5.07	--	--
Cash Flow from Investing Activities	-18.93	-305.45	-4.60	--	--
Cash from Financing Activities	25.82	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	-3.23	211.82	-0.36	0.00	--

Ratios

Profitability Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	11.60	16.20	12.09	25.61	--
ROE (%)	2.13	66.74	14.65	24.87	--
ROA (%)	1.10	4.97	4.06	6.42	--
EBIT Margin (%)	14.97	31.70	26.29	12.34	--
Net Margin (%)	1.28	6.84	7.25	3.90	--
Cash Profit Margin (%)	3.97	9.52	15.04	6.56	--

Growth Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-1.70	15.97	65.29	21.86	--
EBIT Growth (%)	-13.09	29.05	42.04	27.63	--
Net Profit Growth (%)	-73.93	212.90	6.25	7.55	--
EPS Growth (%)	-73.93	278.36	6.25	7.55	--
Book Value Growth (%)	3.34	253.45	15.81	28.51	--

Valuation Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	12.44	17.64	0.00	0.00	--
Price / Book Value	0.26	9.37	0.00	0.00	--
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	4.24	7.33	4.36	1.71	--
Market Cap (₹ Cr)	42.78	6,555.46	0.00	0.00	--

Solvency Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.80	2.39	0.51	1.05	--
Short term debt to equity ratio	0.44	0.18	0.21	0.88	--
Current Ratio	1.48	1.31	0.81	1.04	--
Quick Ratio	0.90	0.84	0.77	0.66	--
Interest Coverage	1.25	2.94	2.57	2.86	--

Operating Efficiency Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	31.10	17.44	42.51	24.27	--
Asset Turnover	0.90	0.72	0.56	1.74	--
Receivable days	90.31	57.17	120.33	81.45	--
Inventory Days	88.40	67.16	9.04	45.36	--
Payable days	12.65	116.25	535.25	134.63	--
Cash Conversion Cycle	166.07	8.07	-393.94	-7.82	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly